Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 15/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 14/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 14/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.60 |
| ▸ | TNKS | O95271 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.60 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.60 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.60 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248569 | 1.00 | TNKS2 (1.00) | TNKS2PARP2PARP15PARP10PARP14 | |
| Sulfuric Acid SCHEMBL11745970 | 0.90 | TNKS2 (0.81) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25324482 | 0.75 | TNKS2 (1.00) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL11743096 | 0.75 | BRPF1 (0.67) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25324487 | 0.75 | PARP2 (1.00) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25322717 | 0.73 | TNKS2 (0.57) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25324791 | 0.72 | TNKS2 (0.78) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25324223 | 0.72 | TNKS2 (1.00) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25324226 | 0.72 | TNKS2 (0.78) | TNKS2PARP2PARP15PARP10PARP14 | |
| SCHEMBL25324784 | 0.72 | TNKS2 (1.00) | TNKS2PARP2PARP15PARP10PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3937713-A | Process for the preparation of s-triazolo[3,4-b]benzothiazoles | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | claimed |
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2025-06-05 | — | — | US | disclosed |
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2025-06-05 | — | — | US | disclosed |
| EP-4469046-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | Oulun Yliopisto (FI) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469046-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | Oulun Yliopisto (FI) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144450-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144450-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2023-08-03 | — | — | WO | disclosed |
| EP-2380208-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-4134914-A | 1-Acyl-4-substituted phenyl thiosemicarbazides | ELI LILLY AND COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4134914-A | 1-Acyl-4-substituted phenyl thiosemicarbazides | ELI LILLY AND COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4082762-A | 4-(2-HALOPHENYL)-1,2,4-TRIAZOLE-3-THIOL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082762-A | 4-(2-HALOPHENYL)-1,2,4-TRIAZOLE-3-THIOL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4075218-A | INSECTICIDES, FUNGICIDES | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4064261-A | TRIAZOLOBENOXAZOLE, TRIAZOLOBENZOTHIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4008242-A | Process for the preparation of s-triazolo{8 3,4-b{9 benzothiazoles | LILLY CO ELI | 1977-02-15 | — | — | US | disclosed |
| US-3974286-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
| US-3937713-A | Process for the preparation of s-triazolo[3,4-b]benzothiazoles | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
| US-3937713-A | Process for the preparation of s-triazolo[3,4-b]benzothiazoles | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
| US-3937713-A | Process for the preparation of s-triazolo[3,4-b]benzothiazoles | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | NAMPT, NADK, NQO1 | TNKS2 29/4885PARP2 15/4885PARP15 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.